NCT03165409View on ClinicalTrials.gov

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

CompletedOBSERVATIONAL
Enrollment

1,828

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Melanoma
Interventions
BIOLOGICAL

Nivolumab

Melanoma intervention

BIOLOGICAL

Ipilimumab

Melanoma intervention

Trial Locations (1)

08540

Bristol-Myers Squibb, Princeton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03165409 - Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread | Biotech Hunter | Biotech Hunter